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xon degeneration occurs frequently in neurode-
generative diseases and peripheral neuropa-
thies. Important insight into the mechanisms of
axon degeneration arose from ﬁndings that the degen-
eration of transected axons is delayed in Wallerian de-
generation slow (Wlds) mice with the overexpression of
a fusion protein with the nicotinamide adenine dinucle-
otide (NAD) synthetic enzyme, nicotinamide mononucle-
otide adenylyltransferase (Nmnat1). Although both Wld
 
s
 
and Nmnat1 themselves are functional in preventing
axon degeneration in neuronal cultures, the underlying
mechanism for Nmnat1- and NAD-mediated axon pro-
A
 
tection remains largely unclear. We demonstrate that
NAD levels decrease in degenerating axons and that
preventing this axonal NAD decline efﬁciently protects
axons from degeneration. In support of a local protec-
tive mechanism, we show that the degeneration of ax-
onal segments that have been separated from their
soma could be prevented by the exogenous application
of NAD or its precursor nicotinamide. Furthermore,
we provide evidence that such Nmnat1/NAD-mediated
protection is primarily mediated by their effects on local
bioenergetics. Together, our results suggest a novel mo-
lecular pathway for axon degeneration.
 
Introduction
 
In addition to neuronal cell death, axon degeneration is a major
morphological change observed in peripheral neuropathies as
well as neurodegenerative diseases like Alzheimer’s disease
(Stokin et al., 2005) and amyotrophic lateral sclerosis (Fischer
et al., 2004). Although cell death represents the irreversible late
phase of degenerative processes, axonal degeneration usually
occurs much earlier, and often precedes or correlates closely
with clinical symptoms such as cognitive decline. However,
the underlying mechanisms for the degeneration of neuronal
processes remain largely elusive.
A useful model for studying the mechanism of axon de-
generation is the self-destructive process observed at the distal
portion of a transected axon after injury, termed Wallerian
degeneration (Waller, 1850). Studies in rodents have estab-
lished that degeneration of distal axons occurs within 24 to 48 h
after axotomy (Coleman and Perry, 2002; Raff et al., 2002).
Interestingly, it appears that an apoptosis-independent mecha-
nism is involved in Wallerian degeneration (Raff et al., 2002),
as such degenerative processes do not seem to involve activa-
tion of the caspase family of cysteine proteases (Finn et al.,
2000). In addition, Wallerian degeneration can be mechanisti-
cally separated from the apoptosis triggered by NGF depriva-
tion in sympathetic neurons (Deckwerth and Johnson, 1994;
Zhai et al., 2003; Brunet et al., 2004).
Initial insight into the molecular mechanisms of Wallerian
degeneration came with the discovery of a spontaneously occur-
ring mutant mouse strain, C57BL/Wld
 
s
 
, whose axons survived
for as long as weeks after transection (Lunn et al., 1989; Glass et
al., 1993). Genetic studies have attributed this slow Wallerian
degeneration phenotype to the overexpression of a fusion protein
(Wld
 
s
 
) that consists of the full-length nicotinamide mononucle-
otide adenylyltransferase (Nmnat1), an enzyme required for both
the de novo and salvage pathways of nicotinamide adenine dinu-
cleotide (NAD) biosynthesis, and a short region of a ubiquitin
assembly protein, UFD2 (Conforti et al., 2000; Mack et al.,
2001). In cultured neurons, although inhibiting the activity of the
ubiquitin proteosome system can slow down Wallerian degener-
ation (Zhai et al., 2003), a recent study demonstrated that overex-
pressing Nmnat1 alone could also prevent the axon degeneration
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triggered by mechanical or chemical insults (Araki et al., 2004).
In addition, this study further suggested that the protective effect
of Nmnat1 is mediated by a NAD-dependent nuclear deacetylase
Sirt1 (Araki et al., 2004), a mammalian homologue of yeast sir2
that has been implicated in regulating life span in yeast (Blander
and Guarente, 2004). Recent studies have demonstrated that in
mammalian cells this NAD-dependent deacetylase activity of
Sirt1 could regulate death/survival decision in response to stress
by down-regulating the p53 tumor suppressor gene (Luo et al.,
2001; Vaziri et al., 2001) and the FOXO transcription factors
(Brunet et al., 2004; Motta et al., 2004). However, previous stud-
ies have shown that NAD levels are not enhanced in the tissues
of Wallerian degeneration slow (Wlds) mice (Mack et al., 2001)
or in cultured neurons overexpressing Wlds or Nmnat1 (Araki et
al., 2004), raising the question as to how Wld
 
s
 
 and Nmnat1 are
involved in axon degeneration. In this study, we provide evi-
dence arguing for the existence of a Sirt1-independent local
mechanism that is involved in NAD-mediated protection.
 
Results and discussion
 
As a first step in examining the role of NAD in Wallerian de-
generation, we used an HPLC method to measure the concen-
tration of NAD and its derivatives in degenerating axons.
Acidic lysates were prepared from axonal segments collected
at different time points after transecting the axons from cul-
tured dorsal root ganglia (DRG) explants (Fig. 1, A and B), and
were resolved by reverse-phase chromatography. At 4 h post-
axotomy when the transected axons were still morphologically
indistinguishable from their uncut controls (Fig. 1, C and D),
NAD levels began to decrease. At 6 h after axotomy, when
early morphological signs of degeneration started to develop
(Fig. 1, A–D), NAD levels declined to almost undetectable.
The observed NAD decline is not due to leakage across the ax-
onal membrane, as other small molecules such as nicotinic acid
(Na) and GDP did not decrease, whereas inosine 5-monophos-
phate (IMP) and AMP increased in the degenerating axons
Figure 1. Reduced NAD levels in degenerating axons. (A) HPLC chromatograms of the axonal segments undergoing Wallerian degeneration. DRG ex-
plants cultured for 5 d were subjected to axonal transection, and the acidic extracts of axonal segments were prepared at the indicated time-points after
transection and analyzed by HPLC. The chromatograms containing NAD and a few other pyridine compounds, including IMP, AMP, and nicotinic acid
(Na) plus GDP from the same amounts of axonal extracts are shown. The absorbance (mAU) was monitored at 260 nm. (B) Quantification of NAD levels
in control and transected axons. NAD levels were normalized against total axonal protein contents and expressed as nmol/mg. The results are presented
from six independent experiments. Statistical analysis was done by t test. ***, P   0.001. (C) Representative phase images of axons undergoing
Wallerian degeneration taken at indicated time-points after transection. Bar, 50  m. (D) Quantification of axon degeneration results. Statistical analysis
was done by t test. ***, P   0.001. 
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(Fig. 1 A). By a similar approach of alkaline extraction (Mich-
eli and Sestini, 1997) it has been difficult for us to detect
NADH in the axonal extracts, presumably due to the low abun-
dance of NADH and the high NAD/NADH ratio reported in
mammalian cells (Zhang et al., 2002; Kasischke et al., 2004).
Thus, we have focused this study on analyzing NAD concentra-
tions. A similar NAD decline was also observed in vincristine-
treated DRG neurons (Fig. S1, available at http://www.jcb.org/
cgi/content/full/jcb.200504028/DC1), another commonly used
axon degeneration model (Wang et al., 2001a; Araki et al.,
2004). These results imply that a decrease in axonal NAD is
common to degenerating axons triggered by both mechanical
and chemical insults.
Next, we examined whether overexpression of Wlds or
Nmnat1 could prevent the NAD decrease in degenerating ax-
ons. To do this, we made recombinant herpes simplex viruses
(HSVs) to express either Wlds fusion protein or the full-length
Nmnat1 in cultured DRG explants and dissociated neurons
(Fig. 2). Consistent with a recent study (Araki et al., 2004), we
found that both Wlds and Nmnat1 proteins significantly slowed
down the degenerative process of transected axonal segments
(Fig. 2, A and B). Neither Wlds nor Nmnat1 significantly in-
creased neuronal NAD levels in intact neurons (unpublished
data). Yet, overexpression of either protein profoundly delayed
the NAD decline in transected axons (Fig. 2 D) in a temporal
pattern similar to their protective effects on axonal degenera-
tion (Fig. 2, A and B). The fact that both Nmnat1 and Wlds pre-
vent the decrease in NAD levels in transected axonal segments
implies that these overexpressed proteins may enhance the
NAD-synthesizing activity in transected axons. Further sup-
porting this hypothesis are the observations that the overex-
pressed Wlds and Nmnat 1 proteins were present not only in
the nuclei of DRG neurons, but also in the axons as determined
by both immunostaining (Wang et al., 2001b) and Western
blotting (Wang et al., 2001b). Thus, our results imply that over-
expressed Wlds/Nmnat1 proteins could exert their protective
effects by synthesizing NAD locally in axons and preventing
NAD decline that resulted from transection.
To definitively determine whether preventing the local de-
crease in NAD levels could result in axon protection, we used
Figure 2. Nmnat1 and Wlds delay both NAD decrease and Wallerian degeneration. (A and B) Wallerian degeneration is delayed by overexpression of
Nmnat1 or Wlds protein. DRG explants were cultured for 5 d and infected with HSVs expressing YFP, Nmnat1, or Wlds 24 h before axotomy. Represen-
tative phase images (A) were taken from transected axonal segments at indicated time-points after transection, and the extents of axon degeneration were
quantified base on phase images (B). Statistical analysis was done by two-way ANOVA using GraphPad Prism software. P   0.001 for both Nmnat1 and
Wlds vs. YFP. Bar, 50  m. (C) Localization of overexpressed Nmnat1 and Wlds proteins. Dissociated DRG neurons were cultured for 5 d and infected
with HSVs expressing YFP or myc-tagged Nmnat1 or Wlds protein (MOI   0.1). 24 h after infection the neurons were fixed and stained with antibodies
against myc (left panels) and Hoechst (middle panels). Bar, 100  m. (D) Both Wlds and Nmnat1 overexpression delay the decline of NAD levels in degen-
erating axons. The DRG explants were infected with HSVs expressing YFP, Nmnat1, or Wlds 24 h before axonal transection. Axonal segments collected
at the indicated time-points were analyzed by HPLC to measure NAD levels. Statistical analysis was done by two-way ANOVA using GraphPad Prism
software. P   0.001 for both Nmnat1 and Wlds vs. YFP. 
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soma-free axonal segments that have been separated from their
cell bodies in the explants as models to examine the protective
effects of different pharmacological treatments. It has been
shown that NAD exogenously applied to the culture medium of
DRG neurons can be transported across the axonal membrane
(Araki et al., 2004). Thus, we first examined the protective ef-
fects of different concentrations of NAD added to the culture
before or after axon transection and removal of ganglia. Consis-
tent with previous observations (Araki et al., 2004), we found
that pretreating DRG explant cultures with NAD 24 h before
transection delayed axon degeneration (Fig. 3, B and C). How-
ever, unlike the NAD concentrations (0.1–1 mM) used by Araki
et al. (2004), we found that only higher concentrations (1–20
mM) of NAD could result in significant protective effects. Sur-
prisingly, we found that the same concentrations of NAD also
efficiently prevented axon degeneration when added at the time
of axon transection (Fig. 3 A), strongly suggesting that locally
supplied NAD is sufficient to prevent axon degeneration.
To further assess the local contribution to this NAD-
dependent protection, we compared the protective effects of 1
and 5 mM NAD provided at different time points before or
after axon transection. As shown in Fig. 3 (B and C), we found
that axons pretreated with NAD for 24 h before transection
were similarly protected as the axons treated with same con-
centrations of NAD added at the time of transection, and even a
few hours after transection (Fig. 3 C). These results suggest
that NAD-mediated protection acts primarily through a local
mechanism in the axons, arguing against a significant contribu-
tion of NAD-induced transcription and other nuclear events. In
this respect, our results are inconsistent with those shown by
Araki et al. (2004), possibly due to the different concentrations
of NAD used in our studies (1–20 mM) as compared with those
by Araki et al. (0.1–1 mM). As additional support for a local
protective effect of NAD, we found that nicotinamide, a pre-
cursor of NAD synthesis, had a similar protective effect even
when applied at the time of axonal transection (Fig. 3 A) or 3 h
after transection (unpublished data). As expected, HPLC analy-
sis indicated that both exogenously applied NAD and nicotin-
amide delayed the decrease of axonal NAD levels triggered by
transection (unpublished data; Fig. 3 D). Together, these results
suggest that NAD could affect the process of axon degenera-
tion through a local protective mechanism.
Figure 3. Exogenously provided NAD and nicotinamide delay Wallerian degeneration in soma-free axonal segments. (A) Wallerian degeneration of
soma-separated axonal segments is delayed by NAD and nicotinamide (NAm) without pretreatment. DRG explants cultured for 5 d were subjected to ax-
onal transection and the ganglia were removed. At the same time, indicated concentrations of NAD or nicotinamide were added to the medium of the
axonal segments only. Quantification of axon degeneration was performed from phase images taken at different time-points after transection. Statistical
analysis was done by two-way ANOVA using GraphPad Prism software. P   0.001 for NAD (5 mM, 20 mM), NAm (5 mM, 25 mM) vs. control. (B and C)
Quantification of the protective effects of 1 mM (B) and 5 mM (C) NAD added at indicated time-points. Pre 24h: NAD added 24 h before transection; pre
0h: NAD added at the same time as transection; post 3, 5, 7 h: NAD added 3, 5, and 7 h post-transection, respectively. Quantification was performed
from phase images taken at indicated time-points (B) or at 12 h after transection (C). Statistical analysis: two-way ANOVA in B: P   0.001 for NAD 1 mM
pre 0 h and 1 mM pre 24 h vs. control; P   0.05 for NAD 1 mM pre 0 h vs. pre 24 h; t test in C: ***, P   0.001. (D) Nicotinamide (NAm) attenuates
NAD decrease in soma-free axonal segments. DRG explants cultured for 5 d were subjected to axonal transection and the ganglia were removed. At the
same time, indicated concentrations of nicotinamide were added to the medium with axonal segments only. The axonal samples were collected at indi-
cated time-points after transection and subjected to HPLC analysis. The results from three independent experiments are presented and statistical analysis
was done by two-way ANOVA using GraphPad Prism software. P   0.001 for 5 mM NAm and 25 mM NAm vs. control. 
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Although Sirt1 has been suggested to be a mediator of this
NAD-dependent protection (Araki et al., 2004), nicotinamide, a
known Sirt1 inhibitor (Luo et al., 2001), could protect axons
from degeneration. On the other hand, NAD is known to be es-
sential for ATP-synthesizing redox reactions that are involved in
glycolysis and oxidative phosphorylation (Shibata et al., 1991).
In particular, cytosolic NAD is required in the glycolytic path-
way for the conversion of glyceraldehyde 3-phosphate to 1,3-
bisphosphoglycerate. Thus, upon cytosolic NAD depletion, glu-
cose can no longer be converted to the pyruvate needed to fuel
oxidative phosphorylation in mitochondria. Considering the sig-
nificant energy demand of various physiological functions in ax-
ons, such as maintenance of membrane potential and axonal
transport, it is conceivable that reduced levels of NAD may im-
pair axonal energy production, thus triggering the onset of axon
degeneration. In support of this, we found that axonal ATP levels
decreased in parallel with NAD levels by HPLC analysis of de-
generating axons (Fig. S2 A, available at http://www.jcb.org/cgi/
content/full/jcb.200504028/DC1). As an additional indicator, we
found that the phosphorylation of AMP-activated protein kinase
(AMPK), known to be activated by an increase in the cellular
AMP/ATP ratio (Kahn et al., 2005), is also induced in degenerat-
ing axonal segments (Fig. S2 B). On the other hand, both overex-
pression of Wlds/Nmnat1 (Fig. 4 A) and exogenously providing
NAD (Fig. 4 B) or nicotinamide (Fig. 4 C) delayed the decrease
of ATP levels in transected axons separated from their somas.
To further assess whether the glycolytic blockade result-
ing from cytosolic NAD depletion contributes to axon degener-
ation, we examined whether the degeneration of axotomized
axons could be suppressed by supplying axons with the glyco-
lytic end product pyruvate, which can be directly used for oxida-
tive phosphorylation in mitochondria. 10 mM methyl-pyruvate,
a membrane-permeable form of pyruvate, has been previously
used to prevent the ATP decrease induced by DNA damage-
induced NAD depletion (Zong et al., 2004). When added at the
time of transection, 10 mM methyl-pyruvate could signifi-
cantly delay the decline of axonal ATP levels (Fig. 4 E) and
also protect axons from degeneration (Fig. 4 D). These results
together suggest that local bioenergetics is an important effec-
tor of NAD depletion in axon degeneration.
Figure 4. Impaired ATP metabolism in degenerating axons. (A) Both Wlds and Nmnat1 delay the decrease of ATP levels in transected axons. 24 h before
axonal transection, DRG explant cultures were infected with HSVs expressing YFP, Wlds, or Nmnat1. The axonal segments were collected at the indicated
times-points after transection and subjected to HPLC analysis. Axonal ATP levels in the axons expressing Wlds and Nmnat1 are expressed as the percent-
ages of that in control YFP-expressing axons (also for B and C). The results from three independent experiments are presented and statistical analysis was
done by two-way ANOVA using GraphPad Prism software. P   0.001 for Wlds and Nmnat1 vs. YFP controls. (B and C) Exogenously provided NAD (B)
and nicotinamide (C) delay the decrease of ATP levels in soma-free axonal segments. Indicated concentration of NAD (B) or nicotinamide (NAm) (C) was
added to the cultures at the same time when the axonal transection was performed. The axonal segments were collected at the indicated time-points after
transection and subjected to HPLC analysis. The results from three independent experiments are presented, and statistical analysis was done by two-way
ANOVA using GraphPad Prism software. P   0.001 for 5 and 20 mM NAD and 25 mM NAm vs. controls; P   0.01 for 5 mM NAm vs. control. (D)
Methyl-pyruvate slows down Wallerian degeneration. 10 mM of methyl-pyruvate was added to the cultures at the same time when the axonal transection
was performed. Quantification of axon degeneration was performed from phase images taken at indicated time-points after transection. Statistical analysis
was done by two-way ANOVA using GraphPad Prism software. P   0.001 for methyl-pyruvate vs. control. (E) Methyl-pyruvate delays the decline of
axonal ATP levels. 10 mM methyl-pyruvate (Py) was added to the cultures at the time of axon transection. The axonal segments were collected at the indi-
cated time-points after transection and subjected to HPLC analysis. The results from three independent experiments are presented and statistical analysis
was done by two-way ANOVA using GraphPad Prism software. P   0.001 for 10 mM methyl-pyruvate vs. controls. 
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Although our results suggest a local mechanism, the nu-
clear deacetylase Sirt1 has recently been implicated to be the
mediator of NAD-dependent axonal protection (Araki et al.,
2004). By RNA interference–mediated gene silencing of each
Sirt1 member (Sirt1-7) in DRG neurons, Araki et al. (2004)
showed that only Sirt1 is involved in mediating the protective
effects of Nmnat1 and NAD. However, we found that pretreat-
ment with NAD 24 h before transection conferred a protective
effect on axon degeneration indistinguishable from the same
concentrations of NAD added at the time of transection (Fig. 3,
B and C), suggesting that NAD-dependent protection is primar-
ily mediated by local events. Furthermore, we did not observe
any significant differences in the extent of Wallerian degenera-
tion or the protective effects of Wlds/Nmnat1/NAD between
neurons from wild-type and Sirt1 knockout mice (McBurney et
al., 2003) (Fig. 5). Although the cause of this discrepancy in re-
sults remains unclear, it is possible that the RNA interference–
mediated knockdown used by Araki et al. (2004) may also affect
the expression of other important genes. In addition, neither
sirtinol, a Sirt1 inhibitor, nor resveratrol, a Sirt1 activator, af-
fected the protective effects of NAD and Wlds/Nmnat1 on axon
degeneration in this same assay (unpublished data). Although
we cannot rule out the possibility that other Sirt family members
can compensate for the loss of Sirt1 function in Sirt1-deficient
neurons, our results strongly support a local bioenergetics
mechanism involved in mediating NAD-dependent protection
against axon degeneration. These findings will provide new in-
sights into designing strategies for preventing and delaying ax-
onal degeneration in patients with Alzheimer’s disease and
other neurodegenerative disorders.
 
Materials and methods
 
Construction and use of recombinant HSV
 
Full-length cDNAs of Wlds and Nmnat1 were amplified from the brain tis-
sues of Wlds mice and confirmed by sequencing. Each construct (both
wild-type and mutant Nmnat1 and Wlds with a myc tag) was then sub-
cloned into the pHSVPrPUC vector. The resulting plasmids were trans-
fected into 2-2 cells with FuGENE 6 (Roche). 24 h after transfection, the
transfected cells were super-infected with 5dl5 HSV helper virus. The re-
combinant virus particles were harvested, amplified, and concentrated as
described previously (Lim and Neve, 1999). Unless indicated, neuronal
cultures were infected with these viruses 24 h before axotomy.
 
Explant cultures and axotomy
 
DRG explants or dissociated neurons from E16 rat embryos were cultured
in medium containing fluorodeoxyuridine and uridine to eliminate nonneu-
ronal cells. The same procedures were used for the experiments using
DRGs from E12.5 to E13 embryos of Sirt1 (
 
 
 
/
 
 
 
) and Sirt1 (
 
 
 
/
 
 
 
) mice.
The genotyping of the mice was performed following the procedure de-
scribed in McBurney et al. (2003). For HSV infection, pilot experiments
were performed to identify the number of HSVs (
 
 
 
3.6 
 
 
 
 10
 
4
 
 HSV units
per explant) that allowed most of the neurons and axons in the explants to
express the protein of interest. For the DRG explant axotomy model, axons
were cut through the axonal halo around each ganglion with a micro-scal-
pel (Fine Science Tools) and the ganglion was removed, leaving only
soma-free axons in the culture dish. To observe the effects of different phar-
macological perturbations on axon degeneration, indicated concentra-
Figure 5. Sirt1 is not required for NAD-dependent
axon protection. (A) Degeneration of DRG axons from
Sirt1 ( / ) and Sirt1 ( / ) mice explant cultures.
DRG explants cultured for 5 d were subjected to ax-
onal transection. At the time of transection, 0 or 5 mM
NAD was added to the medium. Quantification was
performed from phase images taken 0 or 10 h after
transection from duplicate experiments from at least
three mice for each genotype. Statistical analysis was
done by two-way ANOVA. There is no significant dif-
ference in all groups between Sirt1 ( / ) and Sirt1
( / ). (B) The protective effects of overexpressing
Nmnat1 or Wlds on Wallerian degeneration of DRG
neurons from Sirt1 ( / ) and Sirt1 ( / ) mice. Vi-
rally infected DRG explants were subjected to axo-
nal transection. Quantification was performed from
phase images taken at indicated time-points after
transection. Statistical analysis was done by two-way
ANOVA using GraphPad Prism software. There is no
significant difference in all groups between Sirt1
( / ) and Sirt1 ( / ). 
NAD AND AXON DEGENERATION • WANG ET AL.
 
355
 
tions of NAD (Sigma-Aldrich), nicotinamide (Sigma-Aldrich), or methyl-
pyruvate (Sigma-Aldrich) were added to the cultures at the time of transec-
tion or at indicated time-points. Quantification of axon degeneration was
done as described previously (Zhai et al., 2003). In brief, to quantify per-
centages of axons with degeneration from phase images (with beading
and/or fragmented appearance), 300 axons were blindly scored per con-
dition from duplicate explants per experiment, and from three indepen-
dent experiments.
 
Sample preparation and HPLC analysis
 
Sample preparation and HPLC analysis were performed as described by
Micheli and Sestini (1997) with minor modifications. In brief, after extensive
washing, the soma-free axonal segments of 12 DRG explants or 2 
 
 
 
 10
 
5
 
neurons were lysed by 0.3 M ice-cold perchloric acid for 30 min. After
centrifugation (10 min at 12,000 
 
g
 
), the protein content in the precipitates
was measured by the BCA protein assay kit (Pierce Chemical Co.). The
protein-free supernatants were then neutralized to pH 6–7 by adding 1/10
vol of ice-cold 3 M potassium bicarbonate, followed by precipitation on
ice and centrifugation. The cleared samples were stored at 
 
 
 
80
 
 
 
C.
For HPLC analysis, after filtration with a 0.22-mm centrifuge tube fil-
ter (Costar), each sample (100 
 
 
 
l) was resolved on a Luna reverse-phase
C-18 column (3-
 
 
 
m particle size, 75 
 
 
 
 4.6 mm; Phenomenex). The mobile
phase consisted of eluant A (0.1 M KH
 
2
 
PO
 
4
 
 buffer containing 6 mM tet-
rabutylammonium phosphate, pH 5.5) and eluant B (methanol). Each elu-
tion was performed as follows: isocratic phase at 7% solution B for 6 min,
then up to 30% B for 1 min, and then back to initial conditions after 4 min.
Initial conditions are restored in 10 min. The flow rate is 1 ml/min and the
absorbance is monitored at 260 and 280 nm.
 
Western blotting
 
Soma-deprived axons from 12 DRG explants were directly lysed with lysis
buffer (50 mM Tris-HCl, pH 6.8, 100 mM dithiothreitol, 2% SDS, and 10%
glycerol). Aliquots of the resultant lysates with equal amounts of cellular pro-
teins were resolved on 10% SDS-PAGE. The same blots were detected with
antibodies against AMPK and phospho-specific AMPK (Cell Signaling).
 
Microscopy
 
Phase-contrast and fluorescence microscopy were performed at RT with a
microscope (Eclipse TE300; Nikon) with 20
 
 
 
 objective, a Plan-fluor
ELWD 20
 
 
 
/0.45 objective (Nikon), a SPOT diagnostic camera, and
SPOT advanced software. All images were imported into Adobe Photo-
shop 6.0 for contrast manipulation and figure assembly.
 
Online supplemental material
 
Fig. S1 shows that vincristine treatment induces NAD decline in DRG neu-
rons. Fig. S2 shows impaired ATP metabolism in degenerating axons. On-
line supplemental material available at http://www.jcb.org/cgi/content/
full/jcb.200504028/DC1.
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